BioSpace News Archive

Viracta Therapeutics, Inc. (Nasdaq: VIRX), today announced that final data from its Phase 1b/2 trial of Nana-val in relapsed/refractory (R/R) EBV+ lymphoma (VT3996-201) were presented in an oral presentation at the 2021 American Society of Hematology (ASH) Annual Meeting by Bradley Haverkos, M.D., Associate Professor at the University of Colorado School of Medicine.

According to Emergen Research, the global embolotherapy market size was USD 3.50 Billion in 2020 and is expected to reach USD 7.13 Billion in 2028 and register a revenue CAGR of 9.3% during the forecast period, 2021-2028.

According to Emergen Research, the global implantable cardioverter defibrillator market size was USD 7.11 Billion in 2020 and is expected to reach USD 8.81 Billion in 2028 and register a revenue CAGR of 2.7 % during the forecast period, 2021-2028.

Sparrow Pharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug Application (IND) that enables the company to proceed with initiating a phase 2 clinical trial to study SPI-62, a potent and selective investigational HSD-1 inhibitor, for the treatment of Cushing’s disease (CD).

Ryvu Therapeutics (WSE: RVU) a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today announced updated clinical and preclinical data demonstrating the single-agent activity of its two lead oncology drug candidates, RVU120 and SEL24 (MEN1703) at the 63rd American Society of Hematology Annual Meeting.

The Global FemTech Market valued at ~$22 billion (2020) is set to witness healthy growth rate of 15% in the next 5 years.

Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), today announced updated positive data from the Phase 1 dose escalation portion of the AUGMENT-101 trial of SNDX-5613 in patients with mutant nucleophosmin (mNPM1) or mixed lineage leukemia rearranged (MLLr) relapsed/refractory (R/R) acute leukemias.

Kite, a Gilead Company (Nasdaq: GILD), today announced primary results from ZUMA-12, a global, multicenter, single-arm, open-label Phase 2 study evaluating Yescarta® (axicabtagene ciloleucel) as part of first-line treatment in patients with high-risk large B-cell lymphoma (LBCL).

HeartFlow, Inc., the leader in revolutionizing precision heart care, announced it has submitted a 510k premarket application to the U.S. Food and Drug Administration to add advanced anatomic assessment and plaque evaluation to the HeartFlow FFRct Analysis.

Gritstone bio, Inc. announced that the company’s Board of Directors has granted eight employees nonqualified stock options to purchase an aggregate of 38,200 shares of its common stock with an exercise price of $11.58, which is equal to the closing price of Gritstone’s common stock on December 3, 2021, the grant date of the awards.